The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia  by Sonntag, Steffen et al.
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OBJECTIVES We assessed the effects of levosimendan on left ventricular (LV) function in patients with
acute myocardial ischemia and after coronary angioplasty.
BACKGROUND The calcium sensitizer levosimendan improves the function of myocardium in experimental
stunning.
METHODS Twenty-four patients with an acute coronary syndrome underwent angioplasty followed by
double-blinded, randomized treatment with 24 g/kg of levosimendan (n  16) or placebo
(n  8). Left ventricular pressures and volumes were recorded by cineventriculography and
micromanometer-tipped catheters 10 min after angioplasty before drug administration
(baseline) and 20 min after drug administration. Left ventricular function was assessed by the
pressure–volume loop, and regional function analysis by the Slager method.
RESULTS The number of hypokinetic segments decreased with levosimendan, from 8.9  0.9 to 6.5 
1.1 (mean  SEM), as compared with an increase from 7.8  1.0 to 8.5  1.1 with placebo
(p  0.016). A leftward and/or upward shift of the systolic part of the pressure–volume loop,
indicating improved systolic function, was observed in eight of 16 of the levosimendan-
treated and one of eight of the placebo patients (p  0.178). In addition, the single-beat
elastance was increased by levosimendan (p  0.045). The pressure–volume area (p  0.001),
end-systolic pressure (p  0.002), and volume index (p  0.001) were decreased by
levosimendan, but there was no change in the end-systolic pressure–volume ratio. End-
diastolic pressure remained unchanged, whereas the end-diastolic volume index was decreased
by levosimendan (p  0.002). The time constant of isovolumic LV pressure fall decreased
with levosimendan (p  0.001).
CONCLUSIONS Levosimendan improved the function of stunned myocardium without obvious impairment of
diastolic function. (J Am Coll Cardiol 2004;43:2177–82) © 2004 by the American College
of Cardiology Foundation(
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pevosimendan, a novel calcium sensitizer, binds calcium
ependently to troponin C, thus improving systolic function
ithout affecting diastolic function (1–4). This might be of
linical importance in patients with myocardial ischemia,
here systolic dysfunction is usually combined with marked
iastolic dysfunction. Chronically reduced perfusion (hiber-
ating myocardium) or incomplete recovery from previous
schemic episodes (stunned myocardium) might be the
nderlying mechanism of diastolic dysfunction. The patho-
enesis of myocardial stunning and chronic hibernation,
hich may be the result of repetitive episodes of stunning,
as not been established. The major hypotheses are that it is
aused by the generation of oxygen-derived free radicals and
y a transient calcium overload on reperfusion. The radical
nd calcium hypotheses are likely to represent different
acets of the same pathophysiologic cascade. However, the
nal lesion responsible for the contractile depression appears
o be a decreased sensitivity of the myofibrils to calcium
From the *UKB Berlin and Free University Berlin, Berlin, Germany; †Orion
orporation, Espoo, Finland; and ‡Helsinki University Central Hospital, Helsinki,
inland.
Manuscript received December 2, 2002; revised manuscript received January 18,m004, accepted February 18, 2004.5,6). Calcium sensitization might therefore directly im-
rove the function of stunned myocardium (7).
The aims of the present study were to evaluate the effects
f levosimendan on left ventricular (LV) systolic and dia-
tolic function in patients in whom recanalization after an
cute coronary syndrome (ACS) was angiographically
roven or interventionally achieved.
However, levosimendan also acts as an opener of adeno-
ine triphosphate–dependent potassium channels in vascu-
ar smooth muscle cells inducing vasodilation (8,9). Thus,
e chose to study the effect of levosimendan with LV
ressure–volume relationships to aid in the differentiation of
oad alteration from direct myocardial effects.
ETHODS
tudy patients. Male and female patients with ACS (i.e.,
yocardial infarction [MI] or unstable angina; age 18 to 85
ears) were enrolled. The diagnosis of MI was based on the
resence of at least two of the following three criteria: a
linical history of ischemic-type chest discomfort, changes
n serially obtained electrocardiographic tracings (for exam-
le, ST-segment elevation), and a rise in serum cardiac
arkers (elevated cardiac troponin levels, even in patients
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Levosimendan Improves Stunned Myocardium June 16, 2004:2177–82ithout ST-segment elevation or elevated levels of creatine
inase-MB isoenzyme 6% of the creatine kinase level).
atients were eligible if corresponding large akinetic or
ypokinetic regions were diagnosed and coronary angio-
lasty was needed or if spontaneous reperfusion had oc-
urred at the time of coronary angiography.
Patients were ineligible if they had hemodynamically
ignificant valvular or congenital heart disease; used inotro-
ic drugs except digoxin and digitoxin within two days; had
body mass index 32 kg/m2; had end-stage renal failure,
iver cirrhosis, and clinically overt thyrotoxicosis; were
reated with amlodipine or a class IC antiarrhythmic med-
cation. This was a randomized, double-blinded, parallel
roup study assigning patients at a 2:1 ratio to levosimendan
nd placebo, respectively. The study followed the principles
f the Declaration of Helsinki of the World Medical
ssembly, with amendments. The protocol was accepted by
he institutional ethical board, and informed consent was
ocumented from each patient.
reatment regimens. Ten minutes after successful coro-
ary angioplasty, baseline measurement of pressures and
olumes was performed, followed by intravenous infusion of
4 g/kg levosimendan or placebo over 10 min. Twenty
inutes after stopping the infusion, measurements were
epeated.
ethods of assessment. Right and left heart pressures
ere measured by using a Swan Ganz or Cournand right
eart catheter, as well as a Millar micromanometer-tipped
igtail catheter (Millar Instruments, Houston, Texas) for
he LV. The cardiac index was calculated by applying the
ick principle. Left ventricular pressures were digitized
very 0.005 s by means of the Cardis hemodynamic regis-
ration and evaluation system (Schwarzer, Munich, Ger-
any). Left ventriculographic images were acquired at a rate
f 25 frames/s in 30° right anterior oblique and 60° left
nterior oblique projections, using the Philips Integris
ystem (Philips Medical Systems, Hamburg, Germany).
or evaluation of LV function, the DicomView program
Quazar, Hamburg, Germany) and a biplane LV analysis
rogram (Pie Medical Imaging, Maastricht, The Nether-
ands) were used.
The LV endocardial contours were detected by an auto-
ated contour detection system and corrected manually,
rame by frame. Left ventricular volumes were calculated by
impson’s rule and corrected for body surface. Slager wall
otion analysis was performed (10). Based on Slager wall
otion analysis, the number of hypokinetic segments was
ounted (11).
Abbreviations and Acronyms
ACS  acute coronary syndrome
LV  left ventricle/left ventricular
TIMI  Thrombolysis In Myocardial InfarctionEnd-diastolic and end-systolic volumes were determined srom the LV angiogram as the largest or smallest LV volume,
espectively, calculated from serial frames. The diastolic pres-
ure closest to the beginning of the isovolumic contraction
eriod in the differential plot of LV pressure was chosen as the
nd-diastolic pressure (12,13). The quotient of the end-
iastolic pressure by the end-diastolic volume was chosen as
he end-diastolic pressure/volume ratio. The end-systolic
ressure/volume ratio resulted from the division of the end-
ystolic pressure by the end-systolic volume. Left ventricular
ressure–volume loops were constructed by means of the
lotting program Origin (Microcal Software, Northampton,
assachusetts). For the assessment of pressure–volume area,
he pressure–volume loop was integrated.
The end-systolic pressure–volume relationship was esti-
ated from a single cardiac beat by a method based on
ime-varying elastance curves. The time-varying elastance
urves were generated from pressure–volume loops and
ormalized both by amplitude and time to peak amplitude.
ressure and volume data were measured at time tN (range
.25 to 0.35; P[tN] and V[tN]) and tmax (time of end diastole
o maximal pressure/volume ratio; P[tmax] and V[tmax]).
he volume axis intercept V0 was calculated by:
V0 
PNtNVtmax  VtNENtN
PNtN  ENtN
nd
Emax 
Ptmax
VtN  V0
here EN(tN) is the normalized elastance at time tN and
max is the normalized elastance at time tmax (i.e., single-
eat elastance). The single-beat elastance reflects the end-
ystolic pressure–volume relationship (i.e., acute inotropic
hange) (14).
The isovolumic relaxation period was defined as the
eriod from maximum negative derivative of LV pressure to
he time when pressure fell to 5 mm Hg above end-diastolic
ressure of the following beat. The time constant of
sovolumic LV pressure fall () was calculated from both the
ogarithm and derivative of pressure as:
ln p 
1

t B
nd
dp
dt
 
1

p
pB
T
here t is time in ms from maximal dP/dt; B is the natural
ogarithm of LV pressure at maximal negative derivative of
ressure; and pB is the baseline shift due to pleural or
ericardial pressure (15,16).
tatistical analysis. All statistical analyses were done ac-
ording to the intent-to-treat principle and were performed
t a 0.05 level of significance. Demographic features and
ariables evaluating the systolic and diastolic function of
tunned myocardium were summarized with descriptive
tatistics. The main direction of the shift in the pressure–
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June 16, 2004:2177–82 Levosimendan Improves Stunned Myocardiumolume loop from baseline to 20 min was compared between
he two treatment groups using the Fisher exact test.
hanges in other variables of interest were compared
etween the two treatment groups, using the nonparametric
ochran-Mantel-Haenszel test.
ESULTS
wenty-four patients with an ACS, who were admitted to
he intensive care unit, had diagnostic cardiac catheteriza-
ion. Baseline clinical and demographic characteristics were
imilar among the patients (p  0.3). The mean age of the
atients was 60 years (range 37 to 84); their mean body
eight was 80 kg (range 59 to 105); and their mean height
as 172 cm (range 160 to 184). Seventeen male patients (5
lacebo, 12 levosimendan) and seven female patients (3
lacebo, 4 levosimendan) were included.
Twenty-four patients received aspirin (8 placebo, 16
evosimendan), 12 received ticlopidine (4 placebo, 8 levosi-
endan), 23 received heparin (8 placebo, 15 levosimendan),
1 received a beta-blocker (6 placebo, 15 levosimendan), 1
eceived calcium antagonists (levosimendan), 18 received
ngiotensin-converting enzyme inhibitors (4 placebo, 14
evosimendan), 3 received diuretics (levosimendan), and 4
eceived insulin (1 placebo, 3 levosimendan). Six patients (2
lacebo, 4 levosimendan) had diabetes, and only one
evosimendan-treated patient was taking oral hypoglyce-
ics.
able 1. Measurement of Hemodynamics and Systolic and Diast
Levosimendan (n
Baseline
PAP (mm Hg) 34.3  2.2
PAP (mm Hg) 13.3  1.5
PAP (mm Hg) 20.8  1.8
PCWP (mm Hg) 14.8  1.5
AoP (mm Hg) 136  6
AoP (mm Hg) 74  3
AoP (mm Hg) 97  4
R (beats/min) 79  4
VESP (mm Hg) 109  6
VESVI (ml/m1) 36  6
VES P/V ratio (mm Hg/ml) 2.2  0.3
VPV area index (mm Hg ml per m2) 4,287  478
I (l/min per m2) 2.5  0.2
VEF (%) 58  3
max (mm Hg/ml) 2.3  0.4
VEDP (mm Hg) 18.2  1.7
VEDVI (ml/m1) 76  6
VED P/V ratio (mm Hg/ml) 0.13  0.01
eak dP/dt (mm Hg/s) 1,331  82
D (ms) 72  5
L (ms) 54  4
ata are presented as the mean value  SEM.
CI  cardiac index; dAoP  diastolic aortic pressure; dPAP  diastolic pulmona
entricular end-diastolic pressure/volume ratio; LVEDP left ventricular end-diastoli
jection fraction; LVES P/V ratio  left ventricular end-systolic pressure/volume rati
olume index; LVPV  left ventricular pressure–volume area index; mAoP  mean
rtery wedge pressure; Peak dP/dt  maximum rate of fall of ventricular pressure; s
arly diastolic relaxation, calculated from the pressure derivative; L  index of earlyFifteen patients received stents (4 placebo, 11 levosimen- tan), and eight patients underwent percutaneous translumi-
al coronary angioplasty (4 placebo, 4 levosimendan). Cor-
nary angioplasty was not performed in one patient because
f spontaneous restoration of Thrombolysis in Myocardial
nfarction (TIMI) flow grade 3 and minimal coronary
arrowness at the time of cardiac catheterization. Twenty-
hree patients had an acute MI. One patient had unstable
ngina due to chronic single-vessel disease of the left
nterior descending coronary artery; all patients had chest
ain at the time of study inclusion. Thirteen patients (5
lacebo, 8 levosimendan) had anterior or lateral and 11
atients (3 placebo, 8 levosimendan) had inferior or poste-
ior myocardial ischemia. The primary coronary status
evealed TIMI flow grade 0 in 11 patients, grade 1 in 7
atients, grade 2 in 5 patients, and grade 3 in 1 patient (17).
fter reopening of the infarct-related coronary artery, all
atients reached TIMI flow grade 3. The postinterventional
tenosis never exceeded 30%. Distributions of coronary flow
ates and infarct location were similar in the levosimendan
nd placebo patients.
Hemodynamics recorded after coronary angioplasty
baseline), as compared with those recorded after levosi-
endan or placebo infusions (20 min), are shown in Table
and Figure 1. Although a slight decrease in mean aortic
ressure and pulmonary artery pressure, as well as a consid-
rable decrease in pulmonary capillary wedge pressure, was
een in the levosimendan-treated patients, small increases in
unction
6) Placebo (n  8)
p Valuemin Baseline 20 min
 2.1 30.6  2.6 32.2  2.5 0.461
 1.2 11.6  1.8 13.9  2.1 0.004
 1.5 18.5  2.1 20.9  2.4 0.002
 1.6 10.8  1.6 12.1  1.2 0.003
 7 131  9 138  10 0.050
 4 76  5 80  6 0.256
 4 97  6 105  7 0.053
 5 79  4 79  3 0.192
 6 92  7 107  7 0.002
 6 31  4 35  5  0.001
 0.6 1.8  0.3 1.9  0.3 0.221
 456 4,235  857 5,236  808 0.001
 0.2 2.4  0.3 2.4  0.2 0.927
 5 62  4 61  4  0.001
 0.7 2.0  0.3 2.1  0.4 0.045
 1.9 17.6  0.8 17.1  2.3 0.358
 6 76  11 82  10 0.002
 0.02 0.14  0.02 0.12  0.02 0.646
 63 1,375  80 1,537  131 0.340
 4 54  6 66  6 0.001
 3 50  4 51  3 0.053
ry pressure; Emax  single-beat elastance; HR  heart rate; LVED P/V ratio  left
ure; LVEDVI left ventricular end-diastolic volume index; LVEF left ventricular
ESP  left ventricular end-systolic pressure; LVESVI  left ventricular end-systolic
pressure; mPAP  mean pulmonary artery pressure; mPCWP  mean pulmonary
systolic aortic pressure; sPAP  systolic pulmonary artery pressure; D  index of
lic relaxation, calculated by the logarithmic method.olic F
 1
20
32.6
11.1
17.9
10.6
129
72
94
84
92
27
3.0
3,843
2.5
67
3.2
14.9
67
0.12
1,356
57
45
ry arte
c press
o; LV
aortic
AoP 
diastohese pressures were observed with placebo.
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Levosimendan Improves Stunned Myocardium June 16, 2004:2177–82nfluence on systolic function. The total number of hy-
okinetic segments decreased after levosimendan, from 8.9
0.9 (mean  SEM) to 6.5  1.1, although it slightly
ncreased after placebo, from 7.8  1.0 to 8.5  1.1 (p 
.015).
End-systolic pressures and end-systolic volumes de-
reased with levosimendan and increased with placebo. The
jection fraction increased only with levosimendan, whereas
he pressure–volume area decreased with levosimendan and
ncreased with placebo. In addition, levosimendan signifi-
antly increased the single-beat elastance (Table 1, Fig. 1).
n example of a pressure–volume loop is shown in a patient
ho received levosimendan (Fig. 2).
A leftward and/or upward shift of the systolic pressure–
olume relationship, indicating improved systolic function,
as observed in 8 of 16 patients treated with levosimendan
nd in one of eight patients who received placebo. However,
he difference in frequency distribution between levosimen-
an and placebo was not significant (p  0.178).
nfluence on diastolic function. End-diastolic pressures
nd volumes decreased with levosimendan, although they
ere unchanged or increased with placebo. The end-
iastolic pressure/volume ratio was unchanged (Table 1,
ig. 1). A downward and/or rightward shift of the diastolic
art of the pressure–volume loop, indicating improved
iastolic function, was observed in 5 of 16 levosimendan-
reated patients and in five of eight placebo patients. An
pward and/or leftward shift was observed in seven levosi-
igure 1. The mean pulmonary artery pressure (mPAP) and mean pulmo
ddition, the left ventricular end-systolic and end-diastolic volume indexe
entricular ejection fraction (LVEF) was increased.
p  0.05. **p  0.01.endan patients and in one placebo patient. No shift was pbserved in four levosimendan patients or two placebo
atients. It is noteworthy that the shifts were only minor
nd the difference in frequency distribution between levo-
imendan and placebo was not significant (p  0.251). In
ddition, a true upward shift with levosimendan was ob-
erved in only one patient. In another patient, we found an
capillary wedge pressure (mPCWP) were decreased by levosimendan. In
ESVI and LVEDVI) were decreased by levosimendan, whereas the left
igure 2. An example of a pressure–volume loop of a patient receiving
evosimendan is shown. Levosimendan caused a downward shift of the
iastolic part of the pressure–volume loop. It is noteworthy that all shifts
ere only minor and the difference of frequency distribution between
evosimendan and placebo was not significant. LVP  left ventricularnary
s (LVressure; LVV  left ventricular volume.
u
v
t
d
v
s
D
I
s
w
p
t
I
e
i
i
s
s
a
l
s
d
t
p
i
c
a
a
t
a
f
r
M
s
t
d
i
t
c
L
i
m
C
(
g
a
I
t
t
h
d
f
c
d
e
n
c
p
fi
F
p
H
p
s
m
a
p
s
p
f
m
p
a
d
c
a
a
a
C
l
d
R
m
p
G
R
2181JACC Vol. 43, No. 12, 2004 Sonntag et al.
June 16, 2004:2177–82 Levosimendan Improves Stunned Myocardiumpward shift of the early diastolic part of the pressure–
olume loop, whereas in the late diastole it was unchanged.
The index of early diastolic relaxation (), calculated from
he pressure derivative and by the logarithmic method,
ecreased after levosimendan. The maximum rate of fall of
entricular pressure (peak dP/dt) was unchanged by levo-
imendan (Table 1).
ISCUSSION
nfluence on systolic function. The main finding of this
tudy was that after a brief episode of severe ischemia, which
as treated with percutaneous transluminal coronary angio-
lasty, overall and regional LV hypokinesia was improved in
he presence of levosimendan, but not by angioplasty itself.
n previous studies, a nitroprusside-induced reduction of
levated preload and afterload in acute MI resulted in
mprovement of global ventricular function, predominantly
n noninfarcted LV segments (18,19). However, in our
tudy, levosimendan reduced the number of hypokinetic
egments, which suggests an effect of levosimendan beyond
fterload reduction. In an experimental study in dogs,
evosimendan improved regional contractile function of
tunned myocardium after postischemic reperfusion (20).
In the present study, an increased ejection fraction,
ecrease in end-diastolic volume, increased single-beat elas-
ance, and upward/leftward shift of the systolic part of the
ressure–volume loop were observed, consistent with an
mprovement in systolic function. We anticipated an in-
rease in the LV pressure–volume area, but rather observed
decrease. This later finding could be due to levosimendan
lso acting as an afterload-reducing agent. This interpreta-
ion is supported by previous studies (1–4,21,22).
As demonstrated by Colucci et al. (23), intracoronary
dministration of levosimendan might give additional in-
ormation by excluding systemic vasodilation (i.e., afterload
eduction). However, because of very limited data in acute
I, we conceded the systemic application to be safer and
till a source of valuable clinical information (21,23).
In patients with congestive heart failure who were inves-
igated with positron emission tomography, levosimendan
id not show an increase in oxygen consumption, despite an
ncrease in contractility (24,25). This finding is in contrast
o the findings on other positive inotropic drugs like
atecholamines and phosphodiesterase inhibitors (26–28).
evosimendan augments myocardial contractility by bind-
ng to troponin C and stabilizes the calcium-bound confor-
ation of troponin C. The binding of calcium to troponin
is dependent on the intracellular calcium concentration
1–4). In the setting of ischemia, this mechanism distin-
uishes levosimendan from other positive inotropic drugs
nd might be of major importance.
nfluence on diastolic function. However, calcium sensi-
ization might have unfavorable effects on diastole. Never-
heless, studies in dogs and in muscle strips from failing
uman hearts demonstrated that levosimendan improvediastolic function (29,30). The changes in LV diastolic
unction after levosimendan in the present study were
haracterized by a leftward and/or upward shift of the
iastolic pressure–volume curve and a decrease in both
nd-diastolic and end-systolic volume. These changes do
ot necessarily indicate improved diastolic function, but
ould be explained by the effects on systolic function due to
ositive inotropism and afterload reduction. However, the
ndings clearly exclude a deterioration of diastolic function.
urthermore, the early diastolic relaxation showed no im-
airment by levosimendan.
emodynamic effects. A decrease in both systemic and
ulmonary artery pressures was observed. In a previous
tudy, an increase of systolic arterial pressure was found 10
in after coronary angioplasty in patients with acute MI
nd without concomitant medical treatment. The mean
ulmonary artery pressure remained unchanged. In our
tudy, these findings were similar in patients who received
lacebo (31).
When administered to patients with congestive heart
ailure (averaged infusion rate at 6 h: 0.26  0.08 g/kg/
in), levosimendan causes dose-related decreases in mean
ulmonary capillary wedge pressure and mean pulmonary
rtery pressure. In addition, the mean arterial pressure was
ecreased. These hemodynamic effects appeared to be ac-
ompanied by improvement of symptoms and were not
ssociated with a significant increase in the number of
dverse events (21,22).
In our study, the hemodynamic effects in patients with
cute MI were similar, and the drug was well tolerated.
onclusions. In the setting of acute ischemic heart disease,
evosimendan improved the function of stunned myocar-
ium, without obvious impairment of diastolic function.
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ital, Free University Berlin, Warener Strasse 07, D-12683 Berlin,
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